Erratum: An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors (Science Translational Medicine DOI: 10.1126/scitranslmed.3010564);An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors

Science Translational Medicine

Volumn 7, Issue 284, 2015, Pages 284ps10-

  Jonas, Oliver ^a   Landry, Heather M ^a   Fuller, Jason E ^a,b   Santini, John T ^b   Baselga, Jose ^c   Tepper, Robert I ^b,d   Cima, Michael J ^a,e   Langer, Robert ^a,e  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Kibur Medical Inc   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d THIRD ROCK VENTURES   (United States)

^e Massachusetts Institute of Technology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; DOXORUBICIN; GEMCITABINE; LAPATINIB; PACLITAXEL; SUNITINIB; ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE; POLYMER; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TISSUE LEVEL; EQUIPMENT DESIGN; IN VIVO STUDY; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; TRIPLE NEGATIVE BREAST CANCER; TUMOR MICROENVIRONMENT; ANIMAL; APOPTOSIS; BIOPSY; CALIBRATION; CHEMISTRY; DEVICES; DOSE RESPONSE; DRUG MONITORING; DRUG SCREENING; HUMAN; NEOPLASMS; PROCEDURES; PROGNOSIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOMARKERS, TUMOR; BIOPSY; CALIBRATION; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG MONITORING; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MICE; NEOPLASMS; POLYETHYLENE GLYCOLS; POLYMERS; PROGNOSIS;

EID: 84928677711     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aba1552     Document Type: Erratum

References (55)

1. Y. Mouton, L. Dubreuil, In vitro antibiotics testing and its relationship to clinical activity. J. Chemother. 9 (Suppl. 1), 93-99 (1997).
2. F. Merz, F. Gaunitz, F. Dehghani, C. Renner, J. Meixensberger, A. Gutenberg, A. Giese, K. Schopow, C. Hellwig, M. Schäfer, M. Bauer, H. Stöcker, G. Taucher-Scholz, M. Durante, I. Bechmann, Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments. Neuro Oncol. 15, 670-681 (2013).
3. C. Fang, I. Avis, D. Salomon, F. Cuttitta, Novel phenotypic fluorescent three-dimensional platforms for high-throughput drug screening and personalized chemotherapy. J. Cancer 4, 402-415 (2013).
4. R. Straussman, T. Morikawa, K. Shee, M. Barzily-Rokni, Z. R. Qian, J. Du, A. Davis, M. M. Mongare, J. Gould, D.T. Frederick, Z. A. Cooper, P.B. Chapman, D. B. Solit, A. Ribas, R. S. Lo, K. T. Flaherty, S. Ogino, J. A. Wargo, T. R. Golub, Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-504 (2012).
5. T. R. Wilson, J. Fridlyand, Y. Yan, E. Penuel, L. Burton, E. Chan, J. Peng, E. Lin, Y. Wang, J. Sosman, A. Ribas, J. Li, J. Moffat, D. P. Sutherlin, H. Koeppen, M. Merchant, R. Neve, J. Settleman, Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505-509 (2012).
6. E. S. Nakasone, H. A. Askautrud, T. Kees, J. H. Park, V. Plaks, A. J. Ewald, M. Fein, M. G. Rasch, Y. X. Tan, J. Qiu, J. Park, P. Sinha, M. J. Bissell, E. Frengen, Z. Werb, M. Egeblad, Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 21, 488-503 (2012).
7. F. Meric-Bernstam, G. B. Mills, Overcoming implementation challenges of personalized cancer therapy. Nat. Rev. Clin. Oncol. 9, 542-548 (2012).
8. X. Sun, S. Vilar, N. P. Tatonetti, High-throughput methods for combinatorial drug discovery. Sci. Transl. Med. 5, 205rv1 (2013).
9. R. L. Schilsky, Personalized medicine in oncology: The future is now. Nat. Rev. Drug Discov. 9, 363-366 (2010).
10. F. Pammolli, L. Magazzini, M. Riccaboni, The productivity crisis in pharmaceutical R&D. Nat. Rev. Drug Discov. 10, 428-438 (2011).
11. G. Vaidyanathan, Redefining clinical trials: The age of personalized medicine. Cell 148, 1079-1080 (2012).
12. S. Kummar, R. Kinders, L. Rubinstein, R. E. Parchment, A. J. Murgo, J. Collins, O. Pickeral, J. Low, S. M. Steinberg, M. Gutierrez, S. Yang, L. Helman, R. Wiltrout, J. E. Tomaszewski, J. H. Doroshow, Compressing drug development timelines in oncology using phase "0" trials. Nat. Rev. Cancer 7, 131-139 (2007).
13. D. A. LaVan, T. McGuire, R. Langer, Small-scale systems for in vivo drug delivery. Nat. Biotechnol. 21, 1184-1191 (2003).
14. R. Farra, N. F. Sheppard Jr., L. McCabe, R. M. Neer, J. M. Anderson, J. T. Santini Jr., M. J. Cima, R. Langer, First-in-human testing of a wirelessly controlled drug delivery microchip. Sci. Transl. Med. 4, 122ra21 (2012).
15. A. C. R. Grayson, R. S. Shawgo, A. M. Johnson, N. T. Flynn, L. Yawen, M. J. Cima, R. Langer, A BioMEMS review: MEMS technology for physiologically integrated devices. Proc. IEEE 92, 6-21 (2004).
16. H. D. Chirra, T. A. Desai, Multi-reservoir bioadhesive microdevices for independent rate-controlled delivery of multiple drugs. Small 8, 3839-3846 (2012).
17. M. J. Lee, A. S. Ye, A. K. Gardino, A. M. Heijink, P. K. Sorger, G. MacBeath, M. B.Yaffe, Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 149, 780-794 (2012).
18. C. J. Foltz, M. Ullman-Cullere, Guidelines for assessing the health and condition of mice. Lab. Anim. 28, 28-32 (1999).
19. M.Gerlinger, A.J. Rowan, S. Horswell, J. Larkin, D. Endesfelder, E. Gronroos, P. Martinez, N. Matthews, A. Stewart, P. Tarpey, I. Varela, B. Phillimore, S. Begum, N. Q. McDonald, A. Butler, D. Jones, K. Raine, C. Latimer, C. R. Santos, M. Nohadani, A. C. Eklund, B. Spencer-Dene, G. Clark, L. Pickering, G. Stamp, M. Gore, Z. Szallasi, J. Downward, P. A. Futreal, C. Swanton, Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012).
20. V. Almendro, H. J. Kim, Y. K. Cheng, M. Gönen, S. Itzkovitz, P. Argani, A. van Oudenaarden, S. Sukumar, F. Michor, K. Polyak, Genetic and phenotypic diversity in breast tumor metastases. Cancer Res. 74, 1338-1348 (2014).
21. V. Almendro, Y. K. Cheng, A. Randles, S. Itzkovitz, A. Marusyk, E. Ametller, X. Gonzalez-Farre, M. Muñoz, H. G. Russnes, A. Helland, I. H. Rye, A. L. Borresen-Dale, R. Maruyama, A. van Oudenaarden, M. Dowsett, R. L. Jones, J. Reis-Filho, P. Gascon, M. Gönen, F. Michor, K. Polyak, Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Rep. 6, 514-527 (2014).
22. J. H. Baker, K. E. Lindquist, L. A. Huxham, A. H. Kyle, J. T. Sy, A. I. Minchinton, Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts. Clin. Cancer Res. 14, 2171-2179 (2008).
23. L. A. Huxham, A. H. Kyle, J. H. E. Baker, L. K. Nykilchuk, A. I. Minchinton, Microregional effects of gemcitabine in HCT-116 xenografts. Cancer Res. 64, 6537-6541 (2004).
24. A. M. Gonzalez-Angulo, F. Morales-Vasquez, G. N. Hortobagyi, Overview of resistance to systemic therapy in patients with breast cancer. Adv. Exp. Med. Biol. 608, 1-22 (2007).
25. National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology: Colon Cancer (National Comprehensive Cancer Network, Fort Washington, PA, 2011).
26. J. Barretina, G. Caponigro, N. Stransky, K. Venkatesan, A. A. Margolin, S. Kim, C. J. Wilson, J. Lehár, G. V. Kryukov, D. Sonkin, A. Reddy, M. Liu, L. Murray, M. F. Berger, J. E. Monahan, P. Morais, J. Meltzer, A. Korejwa, J. Jané-Valbuena, F. A. Mapa, J. Thibault, E. Bric-Furlong, P. Raman, A. Shipway, I. H. Engels, J. Cheng, G. K. Yu, J. Yu, P. Aspesi Jr., M. de Silva, K. Jagtap, M. D. Jones, L. Wang, C. Hatton, E. Palescandolo, S. Gupta, S. Mahan, C. Sougnez, R. C. Onofrio, T. Liefeld, L. MacConaill, W. Winckler, M. Reich, N. Li, J. P. Mesirov, S. B. Gabriel, G. Getz, K. Ardlie, V. Chan, V. E. Myer, B. L. Weber, J. Porter, M. Warmuth, P. Finan, J. L. Harris, M. Meyerson, T. R. Golub, M. P. Morrissey, W. R. Sellers, R. Schlegel, L. A. Garraway, The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
27. S. L. Holbeck, J. M. Collins, J. H. Doroshow, Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines. Mol. Cancer Ther. 9, 1451-1460 (2010).
28. F. M. Sirotnak, M. F. Zakowski, V. A. Miller, H. I. Scher, M. G. Kris, Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6, 4885-4892 (2000).
29. B. Al-Lazikani, U. Banerji, P. Workman, Combinatorial drug therapy for cancer in the post-genomic era. Nat. Biotechnol. 30, 679-692 (2012).
30. C. L. Dai, A. K. Tiwari, C. P. Wu, X.D. Su, S. R. Wang, D. G. Liu, C. R. Ashby Jr., Y. Huang, R. W. Robey, Y. J. Liang, L. M. Chen, C. J. Shi, S. V. Ambudkar, Z. S. Chen, L. W. Fu, Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res. 68, 7905-7914 (2008).
31. L. Carey, E. Winer, G. Viale, D. Cameron, L. Gianni, Triple-negative breast cancer: Disease entity or title of convenience? Nat. Rev. Clin. Oncol. 7, 683-692 (2010).
32. C. A Hudis, L. Gianni, Triple-negative breast cancer: An unmet medical need. Oncologist 16 (Suppl. 1), 1-11 (2011).
33. J. J. Tao, P. Castel, N. Radosevic-Robin, M. Elkabets, N. Auricchio, N. Aceto, G. Weitsman, P. Barber, B. Vojnovic, H. Ellis, N. Morse, N. T. Viola-Villegas, A. Bosch, D. Juric, S. Hazra, S. Singh, P. Kim, A. Bergamaschi, S. Maheswaran, T. Ng, F. Penault-Llorca, J. S. Lewis, L. A. Carey, C. M. Perou, J. Baselga, M. Scaltriti, Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci. Signal. 7, ra29(2014).
34. L. K. Fung, M. G. Ewend, A. Sills, E. P. Sipos, R. Thompson, M. Watts, O. M. Colvin, H. Brem, W. M. Saltzman, Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res. 58, 672-684 (1998).
35. J. S. Ross, K. Wang, R. N. Al-Rohil, T. Nazeer, C. E. Sheehan, G. A. Otto, J. He, G. Palmer, R. Yelensky, D. Lipson, S. Ali, S. Balasubramanian, J. A. Curran, L. Garcia, K. Mahoney, S. R. Downing, M. Hawryluk, V. A. Miller, P. J. Stephens, Advanced urothelial carcinoma: Next-generation sequencing reveals diverse genomic alterations and targets of therapy. Mod. Pathol. 27, 271-280 (2014).
36. S. Roychowdhury, M. K. Iyer, D. R. Robinson, R. J. Lonigro, Y. M. Wu, X. Cao, S. Kalyana-Sundaram, L. Sam,O. A. Balbin, M. J. Quist, T. Barrette, J. Everett, J. Siddiqui, L. P. Kunju, N. Navone, J. C. Araujo, P. Troncoso, C. J. Logothetis, J. W. Innis, D. C. Smith, C. D. Lao, S. Y. Kim, J. S. Roberts, S. B. Gruber, K. J. Pienta, M. Talpaz, AM. Chinnaiyan, Personalized oncology through integrative high-throughput sequencing: A pilot study. Sci. Transl. Med. 3, 111ra121 (2011).
37. C. L. Arteaga, J. Baselga, Impact of genomics on personalized cancer medicine. Clin. Cancer Res. 18, 612-618 (2012).
38. M. J. Overman, J. Modak, S. Kopetz, R. Murthy, J. C. Yao, M. E. Hicks, J. L. Abbruzzese, AL. Tam, Use of research biopsies in clinical trials: Are risks and benefits adequately discussed? J. Clin. Oncol. 31, 17-22 (2013).
39. A. I. Minchinton, I. F. Tannock, Drug penetration in solid tumours. Nat. Rev. Cancer 6, 583-592 (2006).
40. A. Marusyk, V. Almendro, K. Polyak, Intra-tumour heterogeneity: A looking glass for cancer? Nat. Rev. Cancer 12, 323-334 (2012).
41. S. Di Cosimo, J. Baselga, Management of breast cancer with targeted agents: Importance of heterogeneity. Nat. Rev. Clin. Oncol. 7, 139-147 (2010).
42. S. Banerji, K. Cibulskis, C. Rangel-Escareno, K. K. Brown, S. L. Carter, A. M. Frederick, M. S. Lawrence, A. Y. Sivachenko, C. Sougnez, L. Zou, M. L. Cortes, J. C. Fernandez-Lopez, S. Peng, K. G. Ardlie, D. Auclair, V. Bautista-Piña, F. Duke, J. Francis, J. Jung, A. Maffuz-Aziz, R. C. Onofrio, M. Parkin, N. H. Pho, V. Quintanar-Jurado, A. H. Ramos, R. Rebollar-Vega, S. Rodriguez-Cuevas, S. L. Romero-Cordoba, S. E. Schumacher, N. Stransky, K. M. Thompson, L. Uribe-Figueroa, J. Baselga, R. Beroukhim, K. Polyak, D.C. Sgroi, A.L. Richardson, G. Jimenez-Sanchez, E. S. Lander, S. B. Gabriel, L. A. Garraway, T. R. Golub, J. Melendez-Zajgla, A. Toker, G. Getz, A. Hidalgo-Miranda, M. Meyerson, Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486, 405-409 (2012).
43. F. Sterzing, R. Engenhart-Cabillic, M. Flentje, J. Debus, Image-guided radiotherapy: A new dimension in radiation oncology. Dtsch. Arztebl. Int. 108, 274-280 (2011).
44. D. Habermehl, K. Henkner, S. Ecker, O. Jäkel, J. Debus, S. E. Combs, Evaluation of different fiducial markers for image-guided radiotherapy and particle therapy. J. Radiat. Res. 54 (Suppl. 1), i61-i68 (2013).
45. E. V. Denisov, N. V. Litviakov, M. V. Zavyalova, V. M. Perelmuter, S. V. Vtorushin, M. M. Tsyganov, T. S. Gerashchenko, E. Y. Garbukov, E. M. Slonimskaya, N. V. Cherdyntseva, Intratumoral morphological heterogeneity of breast cancer: Neoadjuvant chemotherapy efficiency and multidrug resistance gene expression. Sci. Rep. 4, 4709 (2014).
46. S. Hoelder, P. A. Clarke, P. Workman, Discovery of small molecule cancer drugs: Successes, challenges and opportunities. Mol. Oncol. 6, 155-176 (2012).
47. J. Orloff, F. Douglas, J. Pinheiro, S. Levinson, M. Branson, P. Chaturvedi, E. Ette, P. Gallo, G. Hirsch, C. Mehta, N. Patel, S. Sabir, S. Springs, D. Stanski, M. R. Evers, E. Fleming, N. Singh, T. Tramontin, H. Golub, The future of drug development: Advancing clinical trial design. Nat. Rev. Drug Discov. 8, 949-957 (2009).
48. C. P. Adams, V. V. Brantner, Spending on new drug development. Health Econ. 19, 130-141 (2010).
49. E. H. Rubin, D. G. Gilliland, Drug development and clinical trials - The path to an approved cancer drug. Nat. Rev. Clin. Oncol. 9, 215-222 (2012).
50. U.S. Food and Drug Administration, Paving the Way for Personalized Medicine: FDA's Roleina New Era of Medical Product Development (U.S. Food and Drug Administration, Silver Spring, MD, 2013); http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/PersonalizedMedicine/UCM372421.pdf).
51. D. A. Berry, Adaptive clinical trials in oncology. Nat. Rev. Clin. Oncol. 9, 199-207 (2011).
52. R. C. Garner, G. Lappin, The phase 0 microdosing concept. Br. J. Clin. Pharmacol. 61, 367-370 (2006).
53. R. Mahajan, K. Gupta, Food and Drug Administration's critical path initiative and innovations in drug development paradigm: Challenges, progress, and controversies. J. Pharm. Bioallied Sci. 2, 307-313 (2010).
54. U.S. Food and Drug Administration, Investigational Device Exemptions (IDEs) for Early Feasibility Medical Device Clinical Studies, Including Certain First in Human (FIH) Studies - Guidance for Industry and Food (U.S. Food and Drug Administration, Silver Spring, MD, 2011), pp. 1-40.
55. J. H. Zheng, C. T. Chen, J. L. Au, M. G. Wientjes, Time- and concentration-dependent penetration of doxorubicin in prostate tumors. AAPS PharmSci 3, E15 (2001).